Thornburg Investment Management Inc. reduced its holdings in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 5.8% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,335,555 shares of the company’s stock after selling 203,966 shares during the quarter. Thornburg Investment Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $52,302,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of the business. TIAA CREF Investment Management LLC raised its holdings in shares of Teva Pharmaceutical Industries by 4.4% in the third quarter. TIAA CREF Investment Management LLC now owns 6,335,449 shares of the company’s stock valued at $136,466,000 after buying an additional 264,693 shares during the last quarter. DNB Asset Management AS raised its holdings in Teva Pharmaceutical Industries by 4.0% during the 4th quarter. DNB Asset Management AS now owns 82,193 shares of the company’s stock worth $1,267,000 after purchasing an additional 3,189 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in Teva Pharmaceutical Industries during the 4th quarter worth about $228,000. Boston Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 18.0% during the 4th quarter. Boston Advisors LLC now owns 23,555 shares of the company’s stock worth $363,000 after purchasing an additional 3,592 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its holdings in Teva Pharmaceutical Industries by 420.3% during the 4th quarter. Quadrant Capital Group LLC now owns 5,541 shares of the company’s stock worth $80,000 after purchasing an additional 4,476 shares during the last quarter. Institutional investors and hedge funds own 67.00% of the company’s stock.
In related news, insider Deborah A. Griffin sold 4,107 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $16.88, for a total value of $69,326.16. Following the completion of the transaction, the insider now directly owns 2,941 shares in the company, valued at approximately $49,644.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Richard Daniell sold 2,098 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $16.88, for a total value of $35,414.24. Following the completion of the transaction, the vice president now owns 2,098 shares of the company’s stock, valued at $35,414.24. The disclosure for this sale can be found here. Insiders sold a total of 11,650 shares of company stock valued at $193,325 over the last quarter. 0.49% of the stock is owned by insiders.
Shares of Teva Pharmaceutical Industries stock traded up $0.23 during trading on Friday, hitting $11.65. 130,971 shares of the company were exchanged, compared to its average volume of 14,472,125. The firm has a market capitalization of $11.74 billion, a P/E ratio of 4.15, a PEG ratio of 1.44 and a beta of 1.30. Teva Pharmaceutical Industries Ltd has a 1-year low of $11.26 and a 1-year high of $25.96. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.66.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $0.57 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 16.84% and a negative net margin of 18.66%. The business had revenue of $4.30 billion during the quarter, compared to analyst estimates of $4.38 billion. During the same period in the previous year, the firm earned $0.94 EPS. Teva Pharmaceutical Industries’s quarterly revenue was down 15.2% compared to the same quarter last year. Research analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.26 EPS for the current fiscal year.
Several analysts have weighed in on TEVA shares. HSBC set a $12.00 price objective on Teva Pharmaceutical Industries and gave the stock a “sell” rating in a report on Tuesday, February 5th. Maxim Group reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, February 14th. Credit Suisse Group dropped their price objective on Teva Pharmaceutical Industries from $26.00 to $20.00 and set a “neutral” rating for the company in a report on Thursday, February 14th. UBS Group started coverage on Teva Pharmaceutical Industries in a report on Thursday, March 7th. They set a “buy” rating and a $22.00 price objective for the company. Finally, SunTrust Banks started coverage on Teva Pharmaceutical Industries in a report on Tuesday, March 19th. They set a “hold” rating and a $17.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $20.53.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: P/E Growth (PEG)
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.